It appears the following feature on November 23rd's CBS Evening News with Scott Pelley may have been referring to Synta trials:
November 23, 2011 7:08 PM
New therapy targets a patient's unique cancer
Hail your posting is becoming desperate. You know that trials with Ganetaspib have shown EXCELLENT SAFETY and EXCELLENT RESULTS. There are those less fortunate that need a drug like Ganetaspib to be successful. I just do not understand why you want Ganetaspib to fail. Get over yourself.
Ain't no one gonna ever fast track any drug of Synta's. Elesclomol took care of that. Nobody will take the risk of finding out that Ganetaspib is killing more people than it helps a year after it is approved...
Synta Presents Results on Ganetespib and Hsp90 Inhibitor Class at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
–Ganetespib highly effective in models of multiple oncogene addicted tumors–
–Ocular toxicities common in 2nd generation Hsp90 inhibitors associated with drug distribution properties–
–Results from a Phase 1 canine clinical trial of ganetespib pro-drug published in PLoS ONE–
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 15, 2011-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that preclinical results presented at the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference show that ganetespib, a potent Hsp90 inhibitor, is highly effective in overcoming mechanisms of resistance in models of multiple oncogene addicted tumors.
“The results presented today and published in PLoS support the potential of ganetespib activity in a broad range of tumor types, including erlotinib-resistant non-small cell lung cancer,” said Vojo Vukovic, M.D., Ph.D, Chief Medical Officer, Synta. “In the clinic, some 2nd generation Hsp90 inhibitors have shown high rates of ocular toxicity. In contrast, ganetespib has a low rate of ocular toxicity. The study of Hsp90 inhibitor distribution profiles within the retina presented today suggests that ocular toxicities seen with Hsp90 inhibitors are likely compound-specific and not a class effect."
The study showed that the retina/plasma exposure ratio and drug elimination rate profile play crucial roles in ocular toxicity seen with many 2nd generation Hsp90 inhibitors. These results suggest that drug distribution properties may explain the differences in level of ocular toxicity observed in the clinic with different Hsp90 inhibitors.
Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that is structurally unrelated to first-generation, ansamycin-family Hsp90 inhibitors such as 17-AAG or IPI-504, and has shown superior activity to these agents in preclinical studies. Ganetespib is currently being evaluated in a broad range of cancer clinical trials, including the global Phase 2b/3 GALAXY TrialTM in non-small cell lung cancer. In these trials ganetespib has shown anti-tumor activity in heavily pretreated patients with lung cancer, breast cancer, and other tumor types and has been well tolerated without severe liver or common ocular toxicities seen with other Hsp90 inhibitors.
"This video has nothing to do with Ganetespib. This video talks about the type of new treatments that threaten to make drugs like Ganetespib irrelevant."
Could very well be INFI's hsp90 drug in the video. Baselga is a HEAVYWEIGHT in oncology....if anything this VALIDATES synta and their hsp90 drug. MGH genotypes every oncology pt and the work described in the video also aptly describes what is being done at ARIA. Targeted therapies! Strong relationship between MGH and ARIA and ridaforolimus is an mTor inhibitor...IMHO both ARIA and SNTA are future stars in this area...
I don't know if the video was talking about this specifically, but for example:
Ganetespib is just a funky chemical that has a novel way of interfering with a cancer's development. The future of cancer treatments is training one's own body's defenses to kill cancer cells.
Here's the video. Can't really tell if this is really referring to Ganetespib:
Can anyone with medical background weigh in on this?